Showing 171-180 of 1073 results for "".
Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Journal Club: A Comprehensive Update
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0DermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, tNew Hope for the Hopeless
https://practicaldermatology.com/issues/august-2025/new-hope-jak-inhibitors-alopecia/36693/Dr. Elizabeth (Lisa) Swanson, a dermatologist and associate medical editor of Practical Dermatology, looks at the critical role of case reports in developing new therapeutic options for patients.The Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouHelp Me Help Replace You
https://practicaldermatology.com/topics/editorial/help-me-help-replace-you/24564/Chief Medical Editor Neal Bhatia, MD, FAAD, reflects on the mix of veteran talent and youthful rising stars that work together to succeed and to evolve in the dermatology field.Managing Office Politics
https://practicaldermatology.com/topics/practice-management/managing-office-politics/19101/Neal Bhatia, MD, Co-Chief Medical Editor of Practical Dermatology® magazine, shares pearls for successfully understanding and navigating the scope of office politics and relationships. DermTube's coverage of the AAD's 2014 Summer Meeting is not endorsed by or affiliated with the American Academy ofDWTV Extra: GPP Awareness Day
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.Medical Dermatology Highlights
https://practicaldermatology.com/programs/practical-dermatology/medical-dermatology-highlights/35889/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, summarizes the various medical dermatology sessions he presented at Music City SCALE 2025.Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database